Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Oct 4 - Oct 9
Clinical trial information is available through ClinicalTrials.gov retatrutide trials
Potentiation and complementation of GLP-1 effects by co-stimulation of GIP (glucose-dependent insulinotropic peptide), glucagon, or amylin and other receptors contribute to additional benefits, opening new horizons in the therapeutic individualization for persons living with obesity
The ongoing phase 3 TRIUMPH trials are evaluating retatrutide across several key populations, including: Adults with obesity (BMI 30 kg/m, or 27 kg/m with weight-related comorbidities) Adults with type 2 diabetes Patients with cardiovascular risk factors the inclusion of a dedicated cardiovascular outcomes component is subject to confirmation via registered trial records
Mild or intermittent pain may be addressed with a primary care provider or urgent care, while persistent or severe symptoms warrant faster assessment
US$ 29.69
US$ 26.29
US$ 20.70
US$ 20.32
US$ 20.32
US$ 24.32
US$ 23.54
